**Table 4. Estimated costs associated with use of gilteritinib**

| | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 |
|---|---|---|---|---|---|
| **Population of eligible patients** | 2 | 2 | 2 | 2 | 2 |
| **Uptake of off-label medicine (%)** | 100 | 100 | 100 | 100 | 100 |
| **Number of patients receiving off-label medicine allowing for discontinuations** | 2 | 4 | 4 | 4 | 4 |
| **Medicine acquisition costs in a market without gilteritinib** | ¶¶ | ¶¶ | ¶¶ | ¶¶ | ¶¶ |
| **Medicine acquisition costs in a market with gilteritinib** | ¶¶ | ¶¶ | ¶¶ | ¶¶ | ¶¶ |
| **Net medicine acquisition costs** | ¶¶ | ¶¶ | ¶¶ | ¶¶ | ¶¶ |
| **Net next-line medicines costs** | £0 | £0 | ¶¶ | ¶¶ | ¶¶ |
| **Net medicine acquisition costs (savings/costs) - including supportive medicines where applicable** | ¶¶ | ¶¶ | ¶¶ | ¶¶ | ¶¶ |
| ¶¶ Commercial in confidence data removed | | | | | |